Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1

Inhibiting human immunodeficiency virus type 1 (HIV-1) infection by blocking the host cell coreceptors CCR5 and CXCR4 is an emerging strategy for antiretroviral therapy. Currently, several novel coreceptor inhibitors are being developed in the clinic, and early results have proven promising. In this...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Strizki, Julie M., Tremblay, Cecile, Xu, Serena, Wojcik, Lisa, Wagner, Nicole, Gonsiorek, Waldemar, Hipkin, R. William, Chou, Chuan-Chu, Pugliese-Sivo, Catherine, Xiao, Yushi, Tagat, Jayaram R., Cox, Kathleen, Priestley, Tony, Sorota, Steve, Huang, Wei, Hirsch, Martin, Reyes, Gregory R., Baroudy, Bahige M.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2005
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1315929/
https://ncbi.nlm.nih.gov/pubmed/16304152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.49.12.4911-4919.2005
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars